JP2006508935A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006508935A5 JP2006508935A5 JP2004544241A JP2004544241A JP2006508935A5 JP 2006508935 A5 JP2006508935 A5 JP 2006508935A5 JP 2004544241 A JP2004544241 A JP 2004544241A JP 2004544241 A JP2004544241 A JP 2004544241A JP 2006508935 A5 JP2006508935 A5 JP 2006508935A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- substituted
- optionally
- compound
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 20
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- -1 methoxy, butoxy Chemical group 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 4
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 3
- 208000012902 Nervous system disease Diseases 0.000 claims 3
- 208000025966 Neurological disease Diseases 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 239000011737 fluorine Substances 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 3
- 230000000926 neurological effect Effects 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 210000002345 respiratory system Anatomy 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000003725 azepanyl group Chemical group 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 239000000460 chlorine Substances 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- YFJCXXMXXDBLTO-UHFFFAOYSA-N (4-methylsulfonylphenyl)-[4-[4-(1-propan-2-ylpiperidin-4-yl)oxyphenyl]piperazin-1-yl]methanone Chemical compound C1CN(C(C)C)CCC1OC1=CC=C(N2CCN(CC2)C(=O)C=2C=CC(=CC=2)S(C)(=O)=O)C=C1 YFJCXXMXXDBLTO-UHFFFAOYSA-N 0.000 claims 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 1
- CSBKEGBTNFFHSO-UHFFFAOYSA-N 3-[4-[4-(3-piperidin-1-ylpropoxy)phenyl]piperazine-1-carbonyl]benzonitrile Chemical compound N1(CCCCC1)CCCOC1=CC=C(C=C1)N1CCN(CC1)C(=O)C=1C=C(C#N)C=CC=1 CSBKEGBTNFFHSO-UHFFFAOYSA-N 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 229920001577 copolymer Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 229910052757 nitrogen Chemical group 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 150000003053 piperidines Chemical class 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0224084.4A GB0224084D0 (en) | 2002-10-16 | 2002-10-16 | Novel compounds |
| PCT/EP2003/011423 WO2004035556A1 (en) | 2002-10-16 | 2003-10-14 | Substituted piperazines, (1,4) diaszepines, and 2,5-diazabicyclo (2.2.1) heptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006231163A Division JP2007016041A (ja) | 2002-10-16 | 2006-08-28 | ヒスタミンｈ１および／もしくはｈ３アンタゴニストまたはｈ３逆アンタゴニストとしての置換ピペラジン、（１，４）ジアゼピン、および２，５−ジアザビシクロ（２．２．１）へプタン。 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006508935A JP2006508935A (ja) | 2006-03-16 |
| JP2006508935A5 true JP2006508935A5 (enExample) | 2006-10-19 |
Family
ID=9946029
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004544241A Pending JP2006508935A (ja) | 2002-10-16 | 2003-10-14 | ヒスタミンｈ１および／もしくはｈ３アンタゴニストまたはｈ３逆アンタゴニストとしての置換ピペラジン、（１，４）ジアゼピン、および２，５−ジアザビシクロ（２．２．１）へプタン。 |
| JP2006231163A Pending JP2007016041A (ja) | 2002-10-16 | 2006-08-28 | ヒスタミンｈ１および／もしくはｈ３アンタゴニストまたはｈ３逆アンタゴニストとしての置換ピペラジン、（１，４）ジアゼピン、および２，５−ジアザビシクロ（２．２．１）へプタン。 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006231163A Pending JP2007016041A (ja) | 2002-10-16 | 2006-08-28 | ヒスタミンｈ１および／もしくはｈ３アンタゴニストまたはｈ３逆アンタゴニストとしての置換ピペラジン、（１，４）ジアゼピン、および２，５−ジアザビシクロ（２．２．１）へプタン。 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7615550B2 (enExample) |
| EP (1) | EP1567511A1 (enExample) |
| JP (2) | JP2006508935A (enExample) |
| KR (1) | KR20050049553A (enExample) |
| CN (2) | CN100400523C (enExample) |
| AU (1) | AU2003280380A1 (enExample) |
| BR (1) | BR0315283A (enExample) |
| CA (1) | CA2502249A1 (enExample) |
| GB (1) | GB0224084D0 (enExample) |
| IS (1) | IS7782A (enExample) |
| MA (1) | MA27482A1 (enExample) |
| MX (1) | MXPA05004078A (enExample) |
| NO (1) | NO20051689L (enExample) |
| NZ (2) | NZ539446A (enExample) |
| PL (1) | PL376477A1 (enExample) |
| RU (1) | RU2328494C2 (enExample) |
| WO (1) | WO2004035556A1 (enExample) |
| ZA (2) | ZA200502873B (enExample) |
Families Citing this family (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7842693B2 (en) | 2002-06-12 | 2010-11-30 | Chemocentryx, Inc. | Substituted piperazines |
| US20050256130A1 (en) * | 2002-06-12 | 2005-11-17 | Chemocentryx, Inc. | Substituted piperazines |
| US7589199B2 (en) | 2002-06-12 | 2009-09-15 | Chemocentryx, Inc. | Substituted piperazines |
| GB0224084D0 (en) * | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| GB0224557D0 (en) | 2002-10-22 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| US20070293216A1 (en) * | 2003-02-14 | 2007-12-20 | Roamware Inc. | Method and system for providing PLN service to inbound roamers in a VPMN using a standalone approach when no roaming relationship exists between HPMN and VPMN |
| CA2521000A1 (en) * | 2003-04-03 | 2004-10-21 | Kyowa Hakko Kogyo Co., Ltd. | Preventive and/or therapeutic agent for neuropathic pain |
| US20060293298A1 (en) * | 2003-04-10 | 2006-12-28 | Bamford Mark J | Compounds |
| GB0316915D0 (en) | 2003-07-18 | 2003-08-20 | Glaxo Group Ltd | Compounds |
| GB0324159D0 (en) | 2003-10-15 | 2003-11-19 | Glaxo Group Ltd | Novel compounds |
| CN1972914A (zh) * | 2004-03-31 | 2007-05-30 | 詹森药业有限公司 | 作为组胺h3受体配合体的非咪唑杂环化合物 |
| WO2005110982A2 (en) | 2004-04-07 | 2005-11-24 | Neurogen Corporation | Substituted 1-benzyl-4-substituted piperazine analogues |
| EP1755605A2 (en) * | 2004-04-15 | 2007-02-28 | Samaritan Pharmaceuticals, Inc. | Use of (4-alkylpiperazinyl)(phenyl) methanones in the treatment of alzheimer's disease |
| RU2386633C2 (ru) * | 2004-05-07 | 2010-04-20 | Мемори Фармасьютиклз Корпорейшн | 1h-индазолы, бензотиазолы, 1, 2-бензоизоксазолы, 1, 2-бензоизотиазолы и хромоны и их получение и применения |
| AU2005310467B2 (en) * | 2004-12-01 | 2011-06-23 | Msd K.K. | Substituted pyridone derivative |
| WO2006090142A1 (en) * | 2005-02-24 | 2006-08-31 | Glaxo Group Limited | l-{4- [ (l-CYCLOBUTYL-4-PIPERIDINYL) OXY] PHENYL] -4-{ [4- (METHYLSULFONYL) PHENYL]CARBONYL PIPERAZINE AS HISTAMINE H3 ANTAGONIST |
| US7951826B2 (en) * | 2005-03-17 | 2011-05-31 | Eli Lilly And Company | Pyrrolidine derivatives as histamine H3 receptor antagonists |
| EP1717235A3 (en) * | 2005-04-29 | 2007-02-28 | Bioprojet | Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands |
| ES2574014T3 (es) * | 2005-05-30 | 2016-06-14 | Msd K.K. | Derivado de piperidina novedoso |
| CN101228127B (zh) * | 2005-05-30 | 2012-05-16 | Msdk.K.公司 | 哌啶衍生物 |
| GB0514812D0 (en) * | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| GB0514811D0 (en) * | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| GB0521563D0 (en) | 2005-10-21 | 2005-11-30 | Glaxo Group Ltd | Novel compounds |
| WO2007048595A1 (en) * | 2005-10-27 | 2007-05-03 | Ucb Pharma, S.A. | Compounds comprising a lactam or a lactam derivative moiety, processes for making them, and their uses |
| WO2007057329A1 (en) * | 2005-11-18 | 2007-05-24 | F. Hoffmann-La Roche Ag | Azaindole-2-carboxamide derivatives |
| ATE507222T1 (de) * | 2005-11-30 | 2011-05-15 | Hoffmann La Roche | 1,1-dioxo-thiomorpholinyl-indolyl-methanon- derivate zur verwendung als h3-modulatoren |
| ES2359739T3 (es) * | 2005-11-30 | 2011-05-26 | F. Hoffmann-La Roche Ag | Derivados de indol-2-il-amida 1,5-sustituida. |
| DE602006014305D1 (de) * | 2005-12-16 | 2010-06-24 | Hoffmann La Roche | Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors |
| AR058109A1 (es) * | 2005-12-20 | 2008-01-23 | Glaxo Group Ltd | Acido 3 - (4 - {[4 -(4 -{[3 - (3, 3 - dimetil - 1 - piperidinil)propil]oxi}fenil) - 1 - piperidinil]carbonil} - 1 - naftalenil)propanoico como antagonistas de los receptotres de histamina h1/h3, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamie |
| EP2013185B1 (en) | 2006-04-20 | 2012-05-30 | Glaxo Group Limited | Novel compounds |
| AU2007242842A1 (en) * | 2006-04-20 | 2007-11-01 | Glaxo Group Limited | 2-substituted 4-benzylphthalazinone derivatives as histamine H1 and H3 antagonists |
| GB0609897D0 (en) * | 2006-05-18 | 2006-06-28 | Glaxo Group Ltd | Compounds |
| NZ573028A (en) * | 2006-05-30 | 2011-11-25 | Janssen Pharmaceutica Nv | Substituted pyridyl amide compounds as modulators of the histamine h3 receptor |
| GB0611587D0 (en) | 2006-06-12 | 2006-07-19 | Glaxo Group Ltd | Novel compounds |
| US9108948B2 (en) | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
| EP2049472B1 (en) | 2006-06-23 | 2015-01-21 | AbbVie Bahamas Ltd. | Cyclopropyl amine derivatives as histamin h3 receptor modulators |
| WO2008002816A1 (en) * | 2006-06-29 | 2008-01-03 | Janssen Pharmaceutica N.V. | Substituted benzamide modulators of the histamine h3 receptor |
| KR101007469B1 (ko) | 2006-12-22 | 2011-01-12 | 성균관대학교산학협력단 | 사스 코로나 바이러스의 ｒｎａ 유사매듭구조에 결합하여 리보솜 틀 이동을 억제하는 호모피페라진계 화합물 |
| PE20081889A1 (es) | 2007-03-23 | 2009-03-05 | Smithkline Beecham Corp | Indol carboxamidas como inhibidores de ikk2 |
| AU2008294708B2 (en) | 2007-09-06 | 2012-03-15 | Glaxo Group Limited | Piperazine derivative having affinity for the histamine H3 receptor |
| JP5465177B2 (ja) | 2007-09-20 | 2014-04-09 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Ｇｐｒ１１９活性のモジュレーターとしての化合物および組成物 |
| WO2009067401A1 (en) | 2007-11-20 | 2009-05-28 | Janssen Pharmaceutica N.V. | Cycloalkyloxy-and hetξrocycloalky- loxypyridine compounds as modulators of the histamine h3 receptor |
| CA2720950A1 (en) * | 2008-04-07 | 2009-10-15 | Irm Llc | Compounds and compositions as modulators of gpr119 activity |
| BRPI0912267A2 (pt) | 2008-05-23 | 2015-10-13 | Amira Pharmaceuticals Inc | sal farmaceuticamente aceitável, composição farmacêutica, artigo de fabricação, métodos para tratar asma, rinite alérgica, doença, lesões gástricas e dor, métodos para prevenir broncoconstrição e rinite alérgica, uso de um sal farmaceuticamente aceitável, e, processo para a preparação de um sal farmaceuticamente aceitável. |
| US8163743B2 (en) | 2008-06-05 | 2012-04-24 | GlaxoGroupLimited | 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases |
| WO2010094643A1 (en) | 2009-02-17 | 2010-08-26 | Glaxo Group Limited | Quinoline derivatives and their uses for rhinitis and urticaria |
| ES2542551T3 (es) | 2009-03-09 | 2015-08-06 | Glaxo Group Limited | 4-Oxadiazol-2-il-indazoles como inhibidores de PI3 cinasas |
| US8354539B2 (en) | 2009-03-10 | 2013-01-15 | Glaxo Group Limited | Indole derivatives as IKK2 inhibitors |
| JP2012520845A (ja) | 2009-03-17 | 2012-09-10 | グラクソ グループ リミテッド | Ｉｔｋ阻害剤として使用されるピリミジン誘導体 |
| US20120029054A1 (en) | 2009-03-19 | 2012-02-02 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA) |
| BRPI1009271A8 (pt) | 2009-03-19 | 2016-02-10 | Merck Sharp & Dohme | Molécula de ácido nucleico interferente curto de filamento duplo, composição farmacêutica, e, método para tratar um indivíduo humano que sofre de uma condição que é mediada pela ação, ou pela perda de ação, de bach1 |
| WO2010107952A2 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| JP2012520686A (ja) | 2009-03-19 | 2012-09-10 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸（ｓｉＮＡ）を用いたシグナル伝達性転写因子６（ＳＴＡＴ６）遺伝子発現のＲＮＡ干渉媒介性阻害 |
| JP2012521764A (ja) | 2009-03-27 | 2012-09-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸（ｓｉＮＡ）を用いた胸腺間質性リンパ球新生因子（ＴＳＬＰ）遺伝子発現のＲＮＡ干渉媒介性阻害 |
| US20120022142A1 (en) | 2009-03-27 | 2012-01-26 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
| US20120004281A1 (en) | 2009-03-27 | 2012-01-05 | Merck Sharp & Dohme Corp | RNA Interference Mediated Inhibition of the Nerve Growth Factor Beta Chain (NGFB) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
| US20100273744A1 (en) | 2009-04-24 | 2010-10-28 | Paul Martin Gore | Compounds |
| US20120035237A1 (en) | 2009-04-24 | 2012-02-09 | Diane Mary Coe | Pyrazole and triazole carboxamides as crac chann el inhibitors |
| US9186353B2 (en) | 2009-04-27 | 2015-11-17 | Abbvie Inc. | Treatment of osteoarthritis pain |
| UY32585A (es) | 2009-04-30 | 2010-11-30 | Glaxo Group Ltd | Nuevos derivados del indazol utiles como inhibidores de la familia fosfoinositida 3´oh quinasa |
| WO2011002984A1 (en) | 2009-07-02 | 2011-01-06 | Cephalon, Inc. | Substituted phenoxypropylcycloamine derivatives as histamine-3 (h3) receptor ligands |
| MX2012004078A (es) * | 2009-10-09 | 2012-07-25 | Irm Llc | Compuestos y composiciones como moduladores de la actividad de gpr119. |
| WO2011067364A1 (en) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Novel compounds |
| JP2013512879A (ja) | 2009-12-03 | 2013-04-18 | グラクソ グループ リミテッド | Ｐｉ３キナーゼの阻害剤としてのベンズピラゾール誘導体 |
| JP2013512880A (ja) | 2009-12-03 | 2013-04-18 | グラクソ グループ リミテッド | Ｐｉ３−キナーゼ阻害剤としてのインダゾール誘導体 |
| WO2011110575A1 (en) | 2010-03-11 | 2011-09-15 | Glaxo Group Limited | Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases |
| GB201007203D0 (en) | 2010-04-29 | 2010-06-16 | Glaxo Group Ltd | Novel compounds |
| WO2012025474A1 (en) | 2010-08-24 | 2012-03-01 | Glaxo Group Limited | Indazole compounds |
| WO2012025473A1 (en) | 2010-08-24 | 2012-03-01 | Glaxo Group Limited | Cc.chemokine receptor 4 antagonists |
| DE112010005848B4 (de) * | 2010-09-06 | 2016-03-10 | Guangzhou Institutes Of Biomedicine And Health, Chinese Academy Of Sciences | Amidverbindungen |
| PL2614058T3 (pl) | 2010-09-08 | 2015-12-31 | Glaxosmithkline Ip Dev Ltd | Polimorfy i sole n-[5-[4-(5-{[(2r,6s)-2,6-dimetylo-4-morfolinylo]-metylo}-1,3-oksazol-2-ilo)-1h-indazol-6-ilo]-2-(metyloksy)-3-pirydynylo]metanosulfonamidu |
| US8853390B2 (en) | 2010-09-16 | 2014-10-07 | Abbvie Inc. | Processes for preparing 1,2-substituted cyclopropyl derivatives |
| WO2012035055A1 (en) | 2010-09-17 | 2012-03-22 | Glaxo Group Limited | Novel compounds |
| WO2012052459A1 (en) | 2010-10-21 | 2012-04-26 | Glaxo Group Limited | Pyrazole compounds acting against allergic, inflammatory and immune disorders |
| EP2630126B1 (en) | 2010-10-21 | 2015-01-07 | Glaxo Group Limited | Pyrazole compounds acting against allergic, immune and inflammatory conditions |
| GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
| US20140005188A1 (en) | 2011-03-11 | 2014-01-02 | Glaxo Group Limited | Pyrido[3,4-b]pyrazine derivatives as syk inhibitors |
| GB201104153D0 (en) | 2011-03-11 | 2011-04-27 | Glaxo Group Ltd | Novel compounds |
| US9428478B2 (en) | 2011-06-13 | 2016-08-30 | Emory University | Piperazine derivatives, compositions, and uses related thereto |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
| KR20160058889A (ko) | 2013-09-22 | 2016-05-25 | 칼리토르 사이언시즈, 엘엘씨 | 치환된 아미노피리미딘 화합물 및 이용 방법 |
| US9233953B2 (en) * | 2013-10-16 | 2016-01-12 | Boehringer Ingelheim International Gmbh | Derivatives of 4-(piperazinylcarbonyl)thiane-1, 1-dione which inhibit GlyT1 |
| KR20160062179A (ko) | 2013-10-17 | 2016-06-01 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 호흡기 질병의 치료를 위한 ｐｉ３ｋ 억제제 |
| EP3057588A1 (en) | 2013-10-17 | 2016-08-24 | GlaxoSmithKline Intellectual Property Development Limited | Pi3k inhibitor for treatment of respiratory disease |
| WO2015069110A1 (en) * | 2013-11-07 | 2015-05-14 | Aapa B.V. | Multiple d2 a(nta)gonists/h3 antagonists for treatment of cns-related disorders |
| EP3122729A4 (en) | 2014-03-28 | 2017-11-15 | Calitor Sciences, LLC | Substituted heteroaryl compounds and methods of use |
| AU2015260841A1 (en) | 2014-05-12 | 2016-12-01 | Glaxosmithkline Intellectual Property (No. 2) Limited | Pharmaceutical compositions comprising danirixin for treating infectious diseases |
| US9938257B2 (en) | 2015-09-11 | 2018-04-10 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| GB201602527D0 (en) | 2016-02-12 | 2016-03-30 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| EP3497100A1 (en) | 2016-08-08 | 2019-06-19 | GlaxoSmithKline Intellectual Property Development Limited | Chemical compounds |
| AU2017311691B2 (en) | 2016-08-18 | 2021-12-02 | Vidac Pharma Ltd. | Piperazine derivatives, pharmaceutical compositions and methods of use thereof |
| GB201706102D0 (en) | 2017-04-18 | 2017-05-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| CN109232549B (zh) * | 2017-07-11 | 2022-07-12 | 江苏恩华药业股份有限公司 | 一种治疗精神分裂症的化合物及其应用 |
| GB201712081D0 (en) | 2017-07-27 | 2017-09-13 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| JP7254076B2 (ja) | 2017-11-19 | 2023-04-07 | サンシャイン・レイク・ファーマ・カンパニー・リミテッド | 置換ヘテロアリール化合物及び使用方法 |
| KR102737185B1 (ko) | 2018-01-20 | 2024-12-05 | 선샤인 레이크 파르마 컴퍼니 리미티드 | 치환된 아미노피리미딘 화합물 및 이의 사용 방법 |
| US10639315B1 (en) | 2019-05-21 | 2020-05-05 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treating Alzheimer's disease |
| US11938139B2 (en) | 2019-04-12 | 2024-03-26 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders |
| US11744833B2 (en) | 2019-04-12 | 2023-09-05 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treatment of insomnia |
| US11690849B2 (en) | 2019-04-12 | 2023-07-04 | LA PharmaTech Inc. | Method of treating dementia |
| US10639314B1 (en) | 2019-04-30 | 2020-05-05 | LA PharmaTech Inc. | Method of treating Alzheimer's disease |
| US10966989B2 (en) | 2019-04-12 | 2021-04-06 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders |
| US11318144B2 (en) | 2019-04-12 | 2022-05-03 | LA PharmaTech Inc. | Compositions and methods for treating Alzheimer's disease and Parkinson's disease |
| US10898493B2 (en) | 2019-04-12 | 2021-01-26 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for psychiatric symptoms of patients with Alzheimer's disease |
| US11389458B2 (en) | 2019-04-12 | 2022-07-19 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treating parkinson's and huntington's disease |
| JP2022536017A (ja) * | 2019-04-30 | 2022-08-12 | ラ ファーマテック インコーポレイテッド | 精神障害、行動障害、認知障害を処置する方法 |
| EP4125919A1 (en) | 2020-03-26 | 2023-02-08 | GlaxoSmithKline Intellectual Property Development Limited | Cathepsin inhibitors for preventing or treating viral infections |
| US11351179B1 (en) | 2021-08-05 | 2022-06-07 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treatment of psychiatric disorders |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2401254A1 (de) | 1974-01-11 | 1975-11-27 | Boehringer Mannheim Gmbh | Neue derivate von n hoch 6-substituierten adeninen |
| IL61897A (en) | 1980-01-19 | 1984-01-31 | Beecham Group Ltd | Benzopyrano(2,3-d)-v-triazoles,their production and pharmaceutical compositions containing them |
| AU685054C (en) | 1992-05-14 | 2003-02-27 | Baylor College Of Medicine | Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy |
| US5364791A (en) | 1992-05-14 | 1994-11-15 | Elisabetta Vegeto | Progesterone receptor having C. terminal hormone binding domain truncations |
| DE4410822A1 (de) | 1994-03-24 | 1995-09-28 | Schering Ag | Neue Piperidin-Derivate |
| US5464788A (en) | 1994-03-24 | 1995-11-07 | Merck & Co., Inc. | Tocolytic oxytocin receptor antagonists |
| USH2007H1 (en) | 1996-01-19 | 2001-12-04 | Fmc Corporation | Insecticidal N-heterocyclylalkyl-or N-[(polycyclyl)alkyl]-N′substituted piperazines |
| US5880128A (en) | 1996-05-08 | 1999-03-09 | Schering Corporation | Carbonyl piperazinyl and piperidinyl compounds |
| WO1999041242A1 (fr) | 1998-02-13 | 1999-08-19 | Rhone-Poulenc Rorer S.A. | Derives de naphtyl disubstitues, leur preparation, les compositions pharmaceutiques qui les contiennent |
| JP4516717B2 (ja) * | 2000-07-13 | 2010-08-04 | アボット・ラボラトリーズ | ヒスタミン−３受容体リガンドとしての１，３−二置換ピロリジン及び１，３，３−三置換ピロリジン並びにそれらの治療的応用 |
| US6620839B2 (en) * | 2000-07-13 | 2003-09-16 | Abbott Laboratories | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications |
| US20030216257A1 (en) | 2000-07-18 | 2003-11-20 | Ingo Sagasser | 1-aryl-4-alkyl halide-2(1h)-pyridones and their use as herbicides |
| ATE354568T1 (de) * | 2000-08-08 | 2007-03-15 | Ortho Mcneil Pharm Inc | Nicht-imidazol aryloxypiperidine als h3 rezeptor liganden |
| US7186732B2 (en) * | 2000-08-08 | 2007-03-06 | Ortho-Mcneil Pharmaceutical, Inc. | Non-imidazole aryloxyalkylamines |
| JP2002173426A (ja) | 2000-12-05 | 2002-06-21 | Ss Pharmaceut Co Ltd | 血糖低下剤 |
| WO2002055496A1 (en) | 2001-01-15 | 2002-07-18 | Glaxo Group Limited | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression |
| AU2002254114A1 (en) * | 2001-03-23 | 2002-10-08 | Eli Lilly And Company | Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses |
| JP4186518B2 (ja) * | 2001-06-15 | 2008-11-26 | アステラス製薬株式会社 | フェニルピリジン誘導体 |
| US7459461B2 (en) | 2001-10-19 | 2008-12-02 | Ortho-Mcneil Pharmaceutical, Inc. | Phosphonic acid compounds as inhibitors of serine proteases |
| IL162859A0 (en) * | 2002-02-05 | 2005-11-20 | Novo Nordisk As | Novel aryl-and heteroarylpiperazines |
| GB0224084D0 (en) * | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| US20060019964A1 (en) | 2002-10-16 | 2006-01-26 | Ancliff Ranchael A | Compounds |
| GB0609897D0 (en) * | 2006-05-18 | 2006-06-28 | Glaxo Group Ltd | Compounds |
-
2002
- 2002-10-16 GB GBGB0224084.4A patent/GB0224084D0/en not_active Ceased
-
2003
- 2003-10-14 NZ NZ539446A patent/NZ539446A/en unknown
- 2003-10-14 RU RU2005110061/04A patent/RU2328494C2/ru not_active IP Right Cessation
- 2003-10-14 CA CA002502249A patent/CA2502249A1/en not_active Abandoned
- 2003-10-14 BR BR0315283-9A patent/BR0315283A/pt not_active IP Right Cessation
- 2003-10-14 CN CNB2003801060141A patent/CN100400523C/zh not_active Expired - Fee Related
- 2003-10-14 MX MXPA05004078A patent/MXPA05004078A/es unknown
- 2003-10-14 WO PCT/EP2003/011423 patent/WO2004035556A1/en not_active Ceased
- 2003-10-14 JP JP2004544241A patent/JP2006508935A/ja active Pending
- 2003-10-14 US US10/531,758 patent/US7615550B2/en not_active Expired - Fee Related
- 2003-10-14 KR KR1020057006621A patent/KR20050049553A/ko not_active Withdrawn
- 2003-10-14 PL PL03376477A patent/PL376477A1/xx unknown
- 2003-10-14 AU AU2003280380A patent/AU2003280380A1/en not_active Abandoned
- 2003-10-14 EP EP03772221A patent/EP1567511A1/en not_active Withdrawn
- 2003-10-14 NZ NZ549963A patent/NZ549963A/en unknown
- 2003-10-14 CN CNA2006101086109A patent/CN101070309A/zh active Pending
-
2005
- 2005-03-31 IS IS7782A patent/IS7782A/is unknown
- 2005-04-05 NO NO20051689A patent/NO20051689L/no not_active Application Discontinuation
- 2005-04-08 ZA ZA200502873A patent/ZA200502873B/en unknown
- 2005-04-29 MA MA28246A patent/MA27482A1/fr unknown
-
2006
- 2006-05-05 ZA ZA200603604A patent/ZA200603604B/en unknown
- 2006-08-28 JP JP2006231163A patent/JP2007016041A/ja active Pending
-
2009
- 2009-09-18 US US12/562,285 patent/US20100075953A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006508935A5 (enExample) | ||
| JP2008513515A5 (enExample) | ||
| ES2345541T3 (es) | Nuevos derivados de 2h-piridazina-3-ona, composiciones farmaceuticas que contienen los mismos y procedimiento para la preparacion del principio activo. | |
| US7790760B2 (en) | Metabotropic glutamate receptor isoxazole ligands and their use as potentiators 286 | |
| ES2434467T3 (es) | Compuestos multicíclicos y métodos para su uso | |
| RU2006105717A (ru) | Производные пиперазина и их применение в качестве терапевтических агентов | |
| JP2012505234A5 (enExample) | ||
| JP2008513498A5 (enExample) | ||
| RU2009120389A (ru) | Гетероциклические соединения в качестве противовоспалительных агентов | |
| JP2005510473A5 (enExample) | ||
| RU2003114748A (ru) | Новые соединения, не являющиеся имидазолами | |
| JP2010539110A5 (enExample) | ||
| AU2002321669A1 (en) | Novel 2H-pyridazine-3-one derivatives, pharmaceutical compositions containing the same and a process for the preparation of the active ingredient | |
| JP2007522142A5 (enExample) | ||
| JP2012530758A5 (enExample) | ||
| JP2005527542A5 (enExample) | ||
| JP2006528147A5 (enExample) | ||
| WO2010000030A1 (en) | Thiazopyrimidinones and uses thereof | |
| JP2005537291A5 (enExample) | ||
| JP2007519618A5 (enExample) | ||
| JP2010513393A5 (enExample) | ||
| JP2009501745A5 (enExample) | ||
| JP2006516626A5 (enExample) | ||
| JP2005508969A5 (enExample) | ||
| JP2010513489A5 (enExample) |